Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Virpax Pharmaceuticals, Inc. - Common Stock (NQ: VRPX )

0.3263 +0.0374 (+12.95%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Virpax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering
From Spartan Capital Securities, LLC
Via GlobeNewswire
Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering
From Spartan Capital Securities, LLC
Via GlobeNewswire
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15
From Virpax Pharmaceuticals
Via Business Wire
Virpax Regains Compliance with Nasdaq Minimum Bid Price
From Virpax Pharmaceuticals
Via Business Wire
Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
From Virpax Pharmaceuticals
Via Business Wire
Virpax Announces Pricing of $2.25 Million Public Offering
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Reports 2023 Year-End Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Announces Leadership Transition
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals
From Virpax Pharmaceuticals
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.